

# SAA

## Serum amyloid A (FIA)

REF: IN057703



25

### Intended use

The infinosi<sup>TM</sup> SAA is a fluorescence immunoassay for the in vitro quantitative determination of Serum amyloid A (SAA) protein in Human serum, plasma or whole blood. For professional use only.

### Summary

References<sup>1-4</sup>

Serum amyloid A (SAA) proteins are a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma. Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs). These proteins are produced predominantly by the liver. The conservation of these proteins throughout invertebrates and vertebrates suggests that SAAs play a highly essential role in all animals.

### Test principle

#### Sandwich principle. Total duration of assay: 15 minutes

Sample is added to the sample well of the test, then the fluorescence-labeled detector anti-SAA antibody binds to SAA antigen in blood specimen. As the sample mixture migrates on the nitrocellulose matrix of test strip by capillary action, the complexes of detector antibody and SAA are captured to anti-SAA antibody that has been immobilized on test strip. Thus the more SAA antigen is in blood specimen, the more complexes are accumulated on test strip. Signal intensity of fluorescence of detector antibody reflects amount of SAA captured and instrument for infinosi<sup>TM</sup> tests shows SAA concentrations in blood specimen.

### Reagents

#### Materials provided

- **Test Cartridge**, 25 pcs, individually packaged
- **ID Chip**, 1 pcs
- **Sample Buffer**, 25 vials
- **IFU**, 1 copy

#### Materials required (but not provided)

- infinosi<sup>TM</sup> 2020 FIA analyzer
- SAA control (DiaSino control is recommended)
- Transfer pipette set (100 µL size)
- Centrifuge (for plasma and serum only)
- Timer

### Precautions and warnings

- For in vitro diagnostic use only.
- Carefully follow the instructions and procedures described in this instructions before testing.
- The test cartridge should remain in its original sealed pouch until ready to use. Do not use it if the pouch is damaged or the seal is broken.
- Do not use reagents beyond the labeled expiry date.
- Do not mix or use components from kits with different Lots.
- Don't use Test Cartridge if its Lot does not match with ID Chip that is inserted onto the instrument.
- The infinosi<sup>TM</sup> SAA should be used only in conjunction with the instrument for infinosi<sup>TM</sup> tests.
- The tests should be applied by professionally trained staff working in certified laboratories at some remove from the patient and clinic at which the sample is taken by qualified medical personnel.
- infinosi<sup>TM</sup> SAA assay is single use only. Do not reuse it.
- The Test Cartridge and instrument for infinosi<sup>TM</sup> tests should be used away from vibration and magnetic field. During normal usage, the Test Cartridge may generate slight vibration, which should be regarded as normal.
- Use separate clean pipette tips and buffer tubes for different specimens. The pipette tips and detector buffer tubes should be used for one specimen only.
- Do not smoke, eat, or drink in areas in which specimens or kit reagents are handled.
- Blood specimens, used test cartridges, pipette tips and sample buffer tubes are potentially infectious. Proper laboratory safety techniques, handling and disposal methods should be followed in accordance with standard procedures and relevant regulations observed by microbiological hazard materials.
- The results should be interpreted by the physician along with clinical findings and other laboratory test results.

### Incident report

Any suspected serious incidents related to this assay shall be immediately reported to DiaSino, DiaSino's Authorized Representative in the EU, and the national competent authorities of the Member States where the users and/or patients are located.

### Storage and stability

- Store the test kit at 2-30°C, the stability is up to the expiration date printed on package.
- Test cartridge and sample buffer should be used within 1 hour after opening the pack.

### Specimen collection and preparation

- The test can be performed with either whole blood, serum or plasma.
- Collect serum samples in accordance with correct medical practices.
- Using standard phlebotomy procedure, collect a venipuncture whole blood specimen using a blood collection tube. If collecting plasma use a blood collection tube containing suitable anticoagulant (EDTA recommended).
- Separate the serum/plasma from blood as soon as possible to avoid hemolysis.
- Test should be performed immediately after the specimens have been collected. Do not leave the specimens at room temperature for prolonged periods. Specimens may be stored at 2-8°C for up to 3 days. For long-term storage, specimens should be kept below -20°C.

### Quality control

- Quality control tests are a part of the good testing practice to confirm the expected results and validity of the assay and should be performed at regular intervals.
- The control tests should be performed immediately after opening a new test lot to ensure the test performance is not altered.
- Quality control tests should also be performed whenever there is any question concerning the validity of the test results.
- Control materials are provided on demand with infinosi<sup>TM</sup> tests. For more information regarding obtaining the control materials, contact [DiaSino Laboratories Co., Ltd](#) for assistance.

### Test setup

- Ensure that the lot number of the cartridge matches that of the sample buffer, and the ID Chip.
- If the sealed cartridge and sample buffer have been stored in refrigerator, place them at room temperature (18-25 °C) at least 30 minutes before measurement.
- Turn on the instrument for infinosi<sup>TM</sup> tests. Refer to the *'instrument for infinosi<sup>TM</sup> tests Operation Manual'* for the complete information and operating instructions.

### Test procedure

1. Insert ID Chip into the instrument for infinosi<sup>TM</sup> tests and read ID chip information.
2. Using a pipette to transfer 5 µL of sample (Human whole blood/plasma/serum) to the **sample buffer tube** provided in the kit.
3. Close the lid of the sample mixing tube and mix the sample thoroughly for **5-10 seconds** by tapping or inverting the tube.
4. Pipette out **100 µL of sample mixture** and load it onto the sample well on the cartridge.
5. Leave the sample-loaded cartridge at room temperature for **15 minutes**.
6. Insert the sample-loaded cartridge into the cartridge holder of instrument for infinosi<sup>TM</sup> tests. Ensure proper orientation of the cartridge before pushing it all the way inside the cartridge holder.
7. Press **"Test"** button on the instrument for infinosi<sup>TM</sup> tests.
8. Instrument for infinosi<sup>TM</sup> tests will start scanning the sample-loaded cartridge immediately.
9. Read the test result on the display screen of the instrument for infinosi<sup>TM</sup> tests.
10. Print out the testing results when press **"Print"** button on the instrument for infinosi<sup>TM</sup> tests.

### Limitations - interference

- This test has been developed for testing human whole blood, serum, plasma specimen only.
- The false positive results include cross-reactions with some components of serum from individual to antibodies, and non-specific adhesion of some components in human blood that have similar epitopes to capture and detector antibodies.

# SAA

## Serum amyloid A (FIA)

- In the case of false negative results, the most common factors are: non-responsiveness of antigen to the antibodies by that certain unknown components are masking its epitope, such that antigen cannot be seen by the antibodies, instability of SAA antigen, resulting in degradation with time and, or temperature, such that they become no longer recognizable by antibodies; and degraded other test components. The effectiveness of the test is highly dependent on storage of kits and sample specimens at optimal conditions.
- Other factors may interfere with Infinosis™ SAA assay and may cause erroneous results. These include technical or procedural errors, as well as additional substances in blood specimens.
- For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

### Measuring range

1.0-200 mg/L (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 1.0 mg/L. Values above the measuring range are reported as > 200 mg/L.

### Lower detection limit

1.0 mg/L

The detection limit represents the lowest analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations above that of the lowest standard (master calibrator, standard 1+2 SD, repeatability study, n = 21).

### Expected value

0-10 mg/L

Expected values may vary with age, sex, diet and geographical location. Each laboratory should determine its own expected values as dictated by good laboratory practice.

### Specific performance data

Representative performance data are given below. Results obtained in individual laboratories may differ.

### Precision

#### Intra-assay

Determined by using 10 replicates of specimen 100 mg/L SAA, CV ≤ 15%

#### Inter-assay

Determined by using 3 replicates for each of three lots using SAA specimen levels at 100 mg/L, CV ≤ 15%.

### Linearity

A serial concentration of SAA controls at 2.0 mg/L, 10 mg/L, 20 mg/L, 50 mg/L, 80 mg/L, and 100 mg/L were each tested for three times, the Correlation Coefficient is:  $r \geq 0.9925$ .

### Method comparison

A comparison of the Infinosis™ SAA assay (y) with the commercially available SAA assay (x) using 227 clinical samples gave the correlation:  $r=0.9656$

### Analytical specificity

The following cross-reactivities were not found:

Cross-reactant	Concentration
Bilirubin	≤ 6 mg/mL
Cholesterol	≤ 75 mg/mL
Triglycerides	≤ 60 mg/mL

### Functional sensitivity

1.2 mg/L

The functional sensitivity is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of ≤ 20 %

### References

- Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant [J]. Eur J Biochem, 1999, 265(2):501-523.
- Urisli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute phase protein, in normal and disease states [J]. Curr Opin Hematol, 2000, 7: 64-69.
- C. M. Uhlar, C. J. Burgess, P M. Sharp, et al. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics [J], 1994, 19 (2):228-235.
- C. M. Uhlar, A. S. Whitehead. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem [J], 1999, 265(2):501-523.

# infinosis™

### Symbols



In vitro diagnostic medical device



Temperature limit



Consult instructions for use



Catalog number



Batch code



Date of manufacture



Use-by date



Contains sufficient for <n> tests



Manufacturer



Do not re-use



Do not use if package is damaged and consult instructions for use



European Conformity



Authorized representative in the European Community



## diasino

DiaSino Laboratories Co., Ltd  
No.68 Jingnansi Road National Eco & Tech Development Area  
Zhengzhou 450000, P.R. China. info@diasino.com



CMC Medical Devices & Drugs S.L.

C/Horacio Lengo N° 18, CP 29006 Málaga, Spain. Tel: +34 9512 14054